期刊文献+

乳腺癌组织中EphA2蛋白的表达及意义 被引量:2

下载PDF
导出
摘要 应用免疫组化法和Western Blot法检测62例乳腺癌标本和18例乳腺良性病变中EphA2蛋白的表达,并分析EphA2表达与乳腺癌临床病理学因素的关系。乳腺癌中EphA2的阳性表达率(85.5%)明显高于乳腺良性病变的阳性率(27.8%)(P<0.01)。Western Blot结果进一步证实了乳腺癌组织高表达EphA2蛋白,而乳腺良性病变组织中检测不到EphA2蛋白条带。Ⅱ、Ⅲ级乳腺癌中EphA2阳性表达率(89.4%、95.9%)明显高于I级乳腺癌(50.0%)(P均<0.05)。雌激素受体(ER)阴性者乳腺癌EphA2的阳性表达率(41.2%)明显高于ER阳性者(14.3%),二者呈明显负相关(r=-0.638,P<0.05)。认为EphA2在乳腺癌组织中表达明显高于乳腺良性病变,并且随乳腺癌恶性程度的增高而增强,提示EphA2有可能是乳腺癌的一个新的标志物。
机构地区 河南省人民医院
出处 《山东医药》 CAS 北大核心 2008年第12期55-56,共2页 Shandong Medical Journal
  • 相关文献

参考文献6

  • 1Hafner C, Schmitz G, Meyer S, et al. Differential gene expression of Eh receptors and ephrins in benign human tissues and cancers [J]. Clln Chem, 2004, 50(3) :490-499.
  • 2Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in overian cancer [J]. Cancer, 2007, 109 (2) :332-340.
  • 3Zelinski DP, Zantek ND, Walker-Daniels J, et al. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase [J]. J Cell Biochem, 2002, 85(4) :714-720.
  • 4Lu M, Miller KD, Gokmen-Polar Y, et al. EphA2 overexpression decreases Estrogen dependence and tamoxifen sensitivity [ J]. Cancer Res, 2003, 63(12) :3425-3429.
  • 5Noblitt LW, Bangari DS, Shukla S, et al. Immunocompetent mouse model of breast cancer for preelinical testing of EphA2-targeted therapy [J]. Cancer Gene Ther, 2005,12(1):46-53.
  • 6Ireton RC and Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics [ J]. Curr Cancer Drug Targets, 2005, 5(3) : 149-157.

同被引文献28

  • 1韩丽萍,乔玉环,董子明,Jahn M.Nesland,索振河.激光捕获显微切割技术检测卵巢癌组织中EphA2受体的表达[J].郑州大学学报(医学版),2009,44(2):368-371. 被引量:2
  • 2陈壬寅,李珊珊.RNA干扰抑制EphA2癌基因在结肠腺癌HCT-8细胞系中的表达[J].中华病理学杂志,2006,35(2):101-105. 被引量:5
  • 3赵瑞皎,吴向华,石必枝,王华茂,李宗海.酪氨酸蛋白激酶受体EphA2及其配体EFNA1在23种肿瘤细胞系中的表达及其意义[J].中国癌症杂志,2007,17(4):320-323. 被引量:6
  • 4Zeng G, Hu Z, KinchM S, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia [ J ]. Am J Pathol,2003,163 (6) : 2271 - 2276.
  • 5Valladares A, Hernandez NG, Gomez FS, et al. Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women [ J]. Cancer Genet Cytogene,2006,170(2): 147- 151.
  • 6Yamaguchi S, Tatsumi T, Takeharat T, et al. Immunotherapy of routine colon cancer using receptor tyrosine kinase EphA2-derlved peptide-pulsed dendritic cell vaccines [ J ]. Cancer,2007,110(7) : 1469 - 1477.
  • 7Abraham S, Knappd W, Cheng L, et al. Expression of EphA2 and EphrinA-1 in carcinoma of the urinary bladder [ J]. Clin Cancer Res ,2006,12(2 ) :353 - 360.
  • 8Hessa R, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenlcmimicry [ J ]. Cancer Biol Ther, 2006, 5 (2) :228 -233.
  • 9Wu D, Suo Z, Kristensen GB, et al. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma [ J ]. Gynecol Oncol, 2004,94 ( 2 ) : 312 - 319.
  • 10Zelinsld DP, Zantek ND, Walker-Daniels J, et al. Estrogen and Mye negatively regulate expression of the EphA2 tyrosine kinase [ J ]. Cell Biochem, 2002, 85 (4) :714 -720.

引证文献2

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部